Detalhe da pesquisa
1.
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study.
Oncology
; 2023 Oct 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37899039
2.
Exposure-response analysis using time-to-event data for bevacizumab biosimilar SB8 and the reference bevacizumab.
Front Pharmacol
; 14: 1288308, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38293674